SCHEMBL19626190

SCHEMBL19626190

CC(C)(C)Oc1cc(F)cc(C2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18355357 0.74 CA12 (0.33) —
SCHEMBL16052704 0.70 LPL (0.42) —
SCHEMBL30518 0.69 PGR (0.40) —
SCHEMBL12745953 0.69 — —
SCHEMBL12254118 0.69 MEN1 (0.33) —
SCHEMBL22498139 0.68 LPL (0.44) —
SCHEMBL17570170 0.67 ACHE (0.33) —
SCHEMBL6764219 0.66 EPAS1 (0.42) —
SCHEMBL21577486 0.66 CYP4F2 (0.30) —
SCHEMBL21577485 0.66 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334919-A1 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS RESPIVERT LTD. (GB) 2017-11-23 — — US disclosed
Send feedback